We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 118

Federal court rejects PMPRB Copaxone decision on excessive prices again

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second

An end to generic claims for innovator profits?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the "NOC Regulations"

Patents and Canadian competition laws

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 22 2013

In Canada, the Competition Act largely defers to the Patent Act. For example, the Act's abuse of dominance provision (s. 79 Canada's

Patented medicines (notice of compliance) listing update

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Listing a patent on the Patent Register maintained by the Minister of Health is the gateway through which an innovator gains access to the provisions

The Supreme Court of Canada holds Pfizer’s Viagra patent invalid

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In a cautionary tale to be heeded by patent drafters, the Supreme Court of Canada held that Pfizer's patent directed to sildenafil, better known as

Generic ordered to pay $1.7 million in accounting of profits

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

On March 12, 2013, the Federal Court released its decision in Apotex Inc. v. H. Lundbeck AS, 2013 FC 192. The Court dismissed Apotex's action to

Authorized generics in the hypothetical world of generic damages

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada, as in other jurisdictions, links drug marketing approval with patent rights. Innovative drug manufacturers may list relevant patents against

Northern exposure?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

Supplemental protection certificates (SPCs): the search for clarity goes on when is a marketing authorisation to be relied on?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 25 2013

In another attempt to clarify the basic criteria for SPC eligibility, Mr. Justice Arnold has referred AstraZeneca AB v Comptroller-General 2012

English courts will take jurisdiction for infringement of foreign patents!

  • Gowling Lafleur Henderson LLP
  • -
  • United Kingdom
  • -
  • March 25 2013

In conjoined cases: Actavis Group hf v Eli Lilly & Company (USA)Medis ehf v Eli Lilly & Company (USA) 2012 EWHC 3316 (Pat), Mr. Justice Arnold has

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy